Det totale antal patienter som havde en bivirkning med sandsynlig eller mulig relation til forsøgsmedicinen, var i det pivotale behandlingsforsøg (MF 4411) 19, 8% for ibandronsyre og 17, 9% for placebo.
The overall proportion of patients who experienced an adverse reaction, i. e. adverse event with a possible or probable relationship to trial medication, in the pivotal treatment study (MF 4411) was 19.8% for ibandronic acid and 17.9% for placebo.